BR112015002706A2 - niclosamida e seus derivados para uso no tratamento de tumores sólidos - Google Patents

niclosamida e seus derivados para uso no tratamento de tumores sólidos

Info

Publication number
BR112015002706A2
BR112015002706A2 BR112015002706A BR112015002706A BR112015002706A2 BR 112015002706 A2 BR112015002706 A2 BR 112015002706A2 BR 112015002706 A BR112015002706 A BR 112015002706A BR 112015002706 A BR112015002706 A BR 112015002706A BR 112015002706 A2 BR112015002706 A2 BR 112015002706A2
Authority
BR
Brazil
Prior art keywords
niclosamide
derivatives
treatment
solid tumors
tumors
Prior art date
Application number
BR112015002706A
Other languages
English (en)
Other versions
BR112015002706A8 (pt
Inventor
Scheffer Björn
Glas Martin
Original Assignee
Life And Brain Gmbh
Rheinische Friedrich Wilhelms Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015002706(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Life And Brain Gmbh, Rheinische Friedrich Wilhelms Univ filed Critical Life And Brain Gmbh
Publication of BR112015002706A2 publication Critical patent/BR112015002706A2/pt
Publication of BR112015002706A8 publication Critical patent/BR112015002706A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
BR112015002706A 2012-08-06 2013-08-06 Niclosamida e seus derivados para uso no tratamento de tumores sólidos BR112015002706A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/065364 WO2014023329A1 (en) 2012-08-06 2012-08-06 Niclosamide and its derivatives for use in the treatment of solid tumors
PCT/EP2013/066484 WO2014023732A1 (en) 2012-08-06 2013-08-06 Niclosamide and its derivatives for use in the treatment of solid tumors

Publications (2)

Publication Number Publication Date
BR112015002706A2 true BR112015002706A2 (pt) 2017-08-08
BR112015002706A8 BR112015002706A8 (pt) 2017-10-10

Family

ID=48917552

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002706A BR112015002706A8 (pt) 2012-08-06 2013-08-06 Niclosamida e seus derivados para uso no tratamento de tumores sólidos

Country Status (15)

Country Link
US (1) US9844522B2 (pt)
EP (1) EP2879671A1 (pt)
JP (1) JP6272861B2 (pt)
CN (1) CN104936586A (pt)
AU (1) AU2013301542A1 (pt)
BR (1) BR112015002706A8 (pt)
CA (1) CA2880916A1 (pt)
CL (1) CL2015000289A1 (pt)
IL (1) IL237125A0 (pt)
MX (1) MX2015001716A (pt)
PE (1) PE20150764A1 (pt)
PH (1) PH12015500252A1 (pt)
RU (1) RU2015107753A (pt)
SG (1) SG11201500912XA (pt)
WO (2) WO2014023329A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016210289A1 (en) 2015-06-24 2016-12-29 Duke University Chemical modulators of signaling pathways and therapeutic use
AU2016315852B2 (en) 2015-09-01 2023-06-15 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
JP2018535190A (ja) * 2015-09-16 2018-11-29 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ Ｐ５３欠損細胞の治療におけるニクロサミドの使用
US10745433B2 (en) 2016-01-12 2020-08-18 Taipei Medical University Compounds for inhibiting cancer and virus
US20170209616A1 (en) * 2016-01-26 2017-07-27 The Procter & Gamble Company Absorbent cores with high molecular weight superabsorbent immobilizer
CN105687171A (zh) * 2016-01-28 2016-06-22 昆明医科大学 一种阿米诺喹的新用途
TWI631944B (zh) 2016-10-14 2018-08-11 長庚大學 氯硝柳胺及其衍生物的用途
EP3784240B1 (en) * 2018-04-24 2023-09-20 Universidade do Minho Wnt6 as glioblastoma oncogenic biomarker, and uses of inhibitors thereof for treating wnt6-overexpressing glioblastoma
US20210179615A1 (en) * 2018-07-30 2021-06-17 Duke University Niclosamide analogues and therapeutic use thereof
WO2021142238A1 (en) * 2020-01-10 2021-07-15 First Wave Bio, Inc. Deuterated niclosamide
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
WO2022124525A1 (ko) * 2020-12-08 2022-06-16 주식회사 대웅제약 니클로사마이드를 포함하는 근육내 및/또는 피하 투여용 약학적 조성물
CN114601833A (zh) * 2022-04-02 2022-06-10 北京大学口腔医学院 一种治疗肿瘤的化学药物组合

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
JP2004515494A (ja) * 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ 治療剤
AU2002354224A1 (en) 2001-12-13 2003-07-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
EP1501465B1 (en) 2002-05-02 2009-10-21 University of Rochester Vectors having both isoforms of beta-hexosaminidase
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
US8163744B2 (en) * 2005-03-18 2012-04-24 Nexuspharma, Inc. Tetrahydro-isoquinolin-1-ones for the treatment of cancer
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
US20130023498A1 (en) * 2008-02-20 2013-01-24 The Wistar Institute and North Carolina State University MicroRNA Modulators and Method for Identifying and Using the Same
US8835506B2 (en) * 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
CA2747154C (en) * 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
JP6228113B2 (ja) * 2011-06-15 2017-11-08 ライフ・アンド・ブレイン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＬＩＦＥ ＡＮＤ ＢＲＡＩＮ ＧｍｂＨ グリア芽腫阻害化合物およびその使用
JP6224597B2 (ja) * 2011-09-27 2017-11-01 バイオメッド バレー ディスカバリーズ，インコーポレイティド グリオーマを処置するための組成物及び方法

Also Published As

Publication number Publication date
CN104936586A (zh) 2015-09-23
PH12015500252A1 (en) 2015-03-30
CL2015000289A1 (es) 2015-06-12
IL237125A0 (en) 2015-03-31
PE20150764A1 (es) 2015-06-04
US20150174086A1 (en) 2015-06-25
WO2014023732A1 (en) 2014-02-13
AU2013301542A1 (en) 2015-02-19
JP2015528437A (ja) 2015-09-28
MX2015001716A (es) 2015-12-08
RU2015107753A (ru) 2016-09-27
BR112015002706A8 (pt) 2017-10-10
SG11201500912XA (en) 2015-04-29
US9844522B2 (en) 2017-12-19
CA2880916A1 (en) 2014-02-13
WO2014023329A1 (en) 2014-02-13
JP6272861B2 (ja) 2018-01-31
EP2879671A1 (en) 2015-06-10

Similar Documents

Publication Publication Date Title
BR112015002706A2 (pt) niclosamida e seus derivados para uso no tratamento de tumores sólidos
SMT201600157B (it) Composti di carbammoilpiridone policiclici e loro uso farmaceutico
HK1216251A1 (zh) 吡唑並吡咯烷衍生物及其治病作用
BR112015001712A2 (pt) uso de s-pindolol para o tratamento da caquexia e sarcopenia
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
CO6751293A2 (es) Derivados heterocíclicos novedosos y su uso en e tratamiento de trastornos neurológicos
BR112012031194A2 (pt) derivados de cisteamina e seu uso no tratamento de ehna
PT3004108T (pt) Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
BR112014016389A8 (pt) composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
BR112014010739A2 (pt) agentes terapêuticos e uso dos mesmos
BR112012030927A2 (pt) fosfaplatinas e seu uso para o tratamento de cânceres
BR112013015378A2 (pt) misturador dinâmico e seu uso
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
BR112013022523A2 (pt) uso de glicopirrolato para o tratamento de taquicardia
BR112015008908A2 (pt) uso de ivermectina e seus derivados e método para desenhar e sintetizar novos derivados
BR112013014540A8 (pt) artigo absorvente e método para preparar o mesmo
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BR112014009456A2 (pt) uso de melatonina para o tratamento e/ou prevenção de mucosite
EP3075379A4 (en) Agent for promoting in vivo absorption of hydroxytyrosol and derivatives thereof and use of same
CL2015001530A1 (es) Uso de inhibidores de telomerasa para el tratamiento de desórdenes mieloproliferativos y neoplasias mieloproliferativas
BR112014027953A2 (pt) nifuratel- (r), seu uso para o tratamento de infecções e síntese de nifuratel -(r) e -(s)
HK1212255A1 (en) Artemisinin and its derivatives for use in the treatment of kidney disease
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.